Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Low-Dose SU Effective for Controlling Blood Glucose: JADEC Study
July 12, 2010
- Banyu, Schering-Plough Reorganize Sales, Marketing Structures
July 12, 2010
- Tasigna Approved in 1st-Line Therapy for Ph+ CML in the US
July 12, 2010
- JUPITER Trial Data on Crestor Biased: Prof. Hamazaki
July 12, 2010
- GSK, MTPC to Terminate Copromotion of Adoair
July 12, 2010
- Sawai Considers Entry into Biosimilars Business
July 12, 2010
- Teijin to Create Its Own Marketing Network in China
July 12, 2010
- RA Patients Highly Satisfied with Biologics Treatment: Pfizer
July 12, 2010
- Pfizer Considers Contract Manufacturing Generics in India
July 12, 2010
- 17 New Drugs Recommended for Approval
July 12, 2010
- Astellas Appoints Naoki Okamura as President of OSI Pharm.
July 12, 2010
- PMDA Reduces Review Period to 19.2 M for Ordinary Products
July 12, 2010
- OD Tablet Tester Marketed by Nipro
July 12, 2010
- Effects of New Premium Must Be Verified: New Chuikyo Pricing Subcommittee Chairman
July 12, 2010
- JMHA to Survey Drugs Purchased by Its Member Hospitals Every Year
July 12, 2010
- JPMA Calls on Its Members Not to Refer to Premium When Negotiating Prices
July 12, 2010
- Eisai Licenses Lorcaserin from Arena in the US
July 12, 2010
- Acute-Stage Hospitals Concerned about Increases in Drug Purchase Costs
July 12, 2010
- Pfizer to Strengthen Drug Discovery Alliances in Japan
July 12, 2010
- Council Recommends Approval for 2 Advanced Therapies
July 12, 2010
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…